Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) analogs are important therapeutics for type 2 diabetes and obesity. Ecnoglutide (XW003) is a novel, long-acting GLP-1 analog. We conducted a Phase 2, randomized, double-blind, placebo-controlled study enrolling 145 adults with T2DM. Participants were randomized to 0.4, 0.8, or 1.2 mg ecnoglutide or placebo as once-weekly injections for 20 weeks. The primary objective was to evaluate the efficacy of ecnoglutide, as measured by HbA1c change from baseline at Week 20. Secondary endpoints included body weight, glucose and lipid parameters, as well as safety. We show that, at end of treatment, the 0.4, 0.8, and 1.2 mg groups had statistically significant HbA1c reductions from baseline of −1.81%, −1.90%, and −2.39%, respectively, compared to −0.55% for placebo (P < 0.0001). At end of treatment, 71.9% of the 1.2 mg group had HbA1c ≤ 6.5% versus 9.1% on placebo, and 33.3% had body weight reductions ≥5% versus 3.0% for placebo. Ecnoglutide was generally safe and well tolerated. China Drug Trials Registry CTR20211014. A Phase 2, randomized, placebo-controlled study evaluated novel GLP-1 analog ecnoglutide in adults with type 2 diabetes. Here we show that ecnoglutide significantly reduced HbA1c from baseline up to -2.39% compared to -0.55% for placebo (P<0.0001), with a safety profile similar to approved GLP-1 analogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results indicate a slightly greater reduction in HbA 1c (0•25% more than dulaglutide, the selective GLP-1 receptor agonist) and bodyweight (3% greater than dulaglutide) 123 in people with type 2 diabetes”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [123]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results indicate a slightly greater reduction in HbA 1c (0•25% more than dulaglutide, the selective GLP-1 receptor agonist) and bodyweight (3% greater than dulaglutide) 123 in people with type 2 diabetes”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [123]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 3×
“…T2DM and obesity are needed to compare ecnoglutide-induced weight loss to other GLP-1 analogs, which included − 2.05 to − 2.45kg for liraglutide (1.2 and 1.8 mg) at 52 weeks 7 , − 3.73 to − 4.53kg for semaglutide (0.5 to 1.0mg) at 30 weeks 8 , and − 5.7kg for semaglutide (1.0mg) at 40 weeks 9 .”
InfluentialGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 2×
“…T2DM and obesity are needed to compare ecnoglutide-induced weight loss to other GLP-1 analogs, which included − 2.05 to − 2.45kg for liraglutide (1.2 and 1.8 mg) at 52 weeks 7 , − 3.73 to − 4.53kg for semaglutide (0.5 to 1.0mg) at 30 weeks 8 , and − 5.7kg for semaglutide (1.0mg) at 40 weeks 9 .”
InfluentialTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 1×
“Dual GLP-1/GIP peptide analogs, such as tirzepa-tide, also show signaling bias for cAMP induction 6 .”
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152 · cited 1×
“The contribution of cAMP bias versus dual GLP-1/GIP targeting to the ef fi cacy of tirzepatide has been a matter of debate 5,12 .”
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Pérez–Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 126
The therapeutic potential of GLP‐1 receptor biased agonism
Jones, B. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15497 · Cited by 107 · cited 2×
“While approved long-acting GLP-1-based peptides, such as semaglutide, dulaglutide, and liraglutide, are full agonists of both cAMP and β -arrestin pathways 5 , ecnoglutide is designed to promote cAMP signaling bias.”
Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
Guo, W., Xu, Z., Zou, H., Li, F., Li, Y., Feng, J., Zhu, Z., Zheng, Q., Zhu, R., Wang, B., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101762 · Cited by 58 · cited 3×
“The ecnoglutide sequence is similar to semaglutide but with signaling bias achieved through the introduction of valine at position 8 4,11 .”
Self-citation
Research works printed but not linked: 1
- International Diabetes Federation. Diabetes prevalence. IDF Diabetes Atlas, 10th edition. 34–38 (2021)
Cited by
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 40
“Newly introduced long-acting GLP-1RAs include ecnoglutide, a modified GLP-1 (7 – 37) peptide containing the substitution Ala 8 → Val and a C-18 fatty acid at Lys 30 [131] and XT002 [132].”
Recent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs
Lindner, S., Keim, S., Haddadzadegan, S., Romero, O. F., Zöller, K., Stern, G., Cesi, I., Kafedjiiski, K., & Bernkop‐Schnürch, A. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503721 · Cited by 24
Metadata
- Authors
- Zhu, D., Wang, W., Tong, G., Ma, G., Ma, J., Han, J., Zhang, X., Liu, Y., Gan, S., Qin, H., Zheng, Q., Ning, J., Zhu, Z., Guo, M., Bu, Y., Li, Y., Jones, C. L., Fenaux, M., Junaidi, M. K., Xu, S., & Pan, H.
- Affiliations
- Nanjing Drum Tower Hospital (CN)
- Heilongjiang University of Chinese Medicine (CN)
- Nanjing First Hospital (CN)
- Daqing City People's Hospital (CN)
- The First People's Hospital of Changde (CN)
- Corresponding author
- Zhu, Dalong
- ORCID
- Venue
- Nature Communications
- Published
- 2024-09-27
- Volume
- 15
- Issue
- 1
- Pages
- 8408-8408
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC11437099
- OpenAlex
- W4402953901
- Cited by
- 34
- References
- 12
- Citations by year
- 2026: 17 · 2025: 16 · 2024: 1
- FWCI
- 11.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Sciwind Biosciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 analogues, type 2 diabetes, glycemic control, HbA1c reduction, weight loss, drug safety, long-acting insulin analogues
- MeSH terms
- Adult, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Treatment Outcome, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. https://app.cochat.ai/papers/10.1038/s41467-024-52353-y
- The paper
- Zhu, D., Wang, W., Tong, G., Ma, G., Ma, J., Han, J., Zhang, X., Liu, Y., Gan, S., Qin, H., Zheng, Q., Ning, J., Zhu, Z., Guo, M., Bu, Y., Li, Y., Jones, C. L., Fenaux, M., Junaidi, M. K., . . . Pan, H. (2024). Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Communications. https://doi.org/10.1038/s41467-024-52353-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.